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Dendritic Cell Targeting of Survivin Protein in a Xenogeneic
Form Elicits Strong CD4ⴙ T Cell Immunity to Mouse
Survivin1
Anna Charalambous, Margarita Oks, Godwin Nchinda, Sayuri Yamazaki,
and Ralph M. Steinman2
To determine whether strong CD4ⴙ T cell immunity could be induced to a nonmutated self protein that is important for tumorigenesis, we selectively targeted the xenogeneic form of survivin, a survival protein overexpressed in tumors, to maturing dendritic
cells in lymphoid tissues. Dendritic cell targeting via the DEC205 receptor in the presence of anti-CD40 and poly(I:C) as maturation stimuli, induced strong human and mouse survivin-specific CD4ⴙ T cell responses, as determined by IFN-␥, TNF-␣, and
IL-2 production, as well as the development of lytic MHC class II-restricted T cells and memory. Immunity was enhanced further
by depletion of CD25ⴙfoxp3ⴙ cells before vaccination. anti-DEC205-human survivin was superior in inducing CD4ⴙ T cell
responses relative to other approaches involving survivin plasmid DNA or survivin peptides with adjuvants. However, we were
unable to induce CD8ⴙ T cell immunity to survivin by two doses of DEC205-targeted survivin or the other strategies. Therefore,
significant CD4ⴙ T cell immunity to a self protein that is overexpressed in most human cancers can be induced by DEC205
targeting of the Ag in its xenogeneic form to maturing DCs. The Journal of Immunology, 2006, 177: 8410 – 8421.

T

umor cells express a number of changes that can be recognized as Ags by lymphocyte clones within the vast B
and T cell repertoires generated in the bone marrow
(BM)3 and thymus (1). Ab and T cell-mediated mechanisms directed to these Ags are able to reject tumors, but primarily when
given as passive immunotherapies either as preformed Abs (2, 3)
or immune T cells (4, 5). It has been more demanding to actively
induce strong B and T cell immunity against tumor Ags. Toward
this end, the targeting of tumor Ags directly to immunogenic dendritic cells (DC) in vivo offers a logical route to increasing antitumor immunity. In this study, we set out to address this proposal
in the context of inducing CD4⫹ helper T cells specific for survivin, a self protein that is overexpressed in a nonmutated form in
most tumors and is likely to contribute to tumorigenesis.
The CD4⫹ helper T cell is attracting increased interest as a
mediator of tumor resistance. First, CD4⫹ T cells can mediate
tumor rejection independently of CD8⫹ killer T cells, for example,
through activation and recruitment of NK cells, macrophages, and
eosinophils (6 –9). In these cases, vaccination with tumor cells
completely lacking MHC class I (MHC-I) expression resulted in
tumor rejection that was comparable to that seen against a challenge with an MHC-I-positive variant of the same tumor. Prior
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depletion of either CD4⫹ T cells or NK cells, but not CD8⫹ T
cells, resulted in an inability to reject the MHC-I-negative variant
(10). Additionally, in CD8 knockout mice, CD4⫹ T cells and NK
cells were the primary mediators of protection against a B16 melanoma tumor challenge, following vaccination with AdVMART1
gene-modified DCs (9). CD4⫹ T cells also stimulate the innate arm
of the immune system at the tumor site and inhibit local angiogenesis (6, 11). Other mechanisms for tumor rejection involve the
production of IFN-␥ (6) and inducible NO synthase by CD4⫹ T
cells (7). These results suggest that CD4⫹ T cells can provide
tumor resistance through CD8-independent mechanisms.
Second, CD4⫹ T cells can help CD8⫹ T cells during the priming and maintenance of CD8⫹ T cell memory, i.e., stronger and
better T cell responses upon a secondary exposure to Ag (12–14).
Although short-term Ag stimulation in the absence of CD4⫹ T cell
help is sufficient to trigger a program of CTL differentiation that
includes multiple rounds of division, effector function and contraction (15–17), CD4⫹ T cells are required to either program or
maintain the final step of CD8⫹ T cell differentiation into functional memory cells (14), possibly by producing IL-2 (18).
We have chosen to study CD4⫹ T cell responses to a conserved self
protein, survivin. This 16.5-kDa protein is not highly expressed in
most adult tissues but is required during early thymocyte development
for the transition from CD4⫺CD8⫺ double-negative thymocytes to
CD4⫹CD8⫹ double-positive cells (19). Survivin becomes prominent
in fast-growing cells such as transformed cell lines and human cancers
(20, 21). Survivin is expressed during the G2-M phase of the cell
cycle in a regulated manner (22), and its interaction with the mitotic
spindle apparatus (microtubules, centromeres, and intracellular midbodies) (23, 24) could be essential for its ostensible antiapoptotic
function (25). Overexpression of survivin has oncogenic potential because it may overcome the G2-M-phase checkpoint to enforce progression of cells through mitosis. Because survivin inhibits processing
of downstream effector caspase-3 and caspase-7 in cells receiving an
apoptotic stimulus (22), its overexpression in tumors could be implicated in the resistance to a variety of proapoptotic stimuli, including
chemotherapy. In fact, survivin overexpression in tumors is associated
0022-1767/06/$02.00
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with an unfavorable course of disease, including accelerated progression, higher rates of recurrences, increased resistance to therapy, and
shortened survival (26, 27). Down-regulation of survivin expression
in various tumor cell lines, induced by antisense compounds, reduces
tumor growth potential and promotes tumor cell apoptosis (28, 29).
Furthermore, injection of human MCF-7 breast cancer xenografts
with replication-deficient adenoviruses encoding a phosphorylationdefective survivin Thr343 Ala (pAd-T34A) dominant-negative mutant, was shown to inhibit growth of established tumors and trigger
tumor cell apoptosis in vivo (30).
We postulated that the relatively low levels of survivin expression in the thymus and periphery might limit the extent of immunological tolerance in the CD4⫹ T cell compartment. We evaluated different approaches for inducing CD4⫹ T cell immunity to
this protein comparing human or xenogeneic survivin (hsurvivin)
to the mouse protein (which are 85% homologous) in BALB/c
mice. We will report that one specific strategy, the incorporation of
hsurvivin into the H chain of anti-DEC205 mAb, allowed for the
induction of strong CD4⫹ T cell responses that cross-reacted with
mouse survivin (msurvivin). DEC205 is a receptor for Ag uptake
and processing that is expressed at high levels on a subset of DCs
in lymphoid tissues. DEC205/CD205 targeting has been shown
previously to be highly immunogenic for foreign microbial proteins (31–33). Now we find that targeting of a self-Ag via DEC205
elicits a CD4⫹ T cell response that involves high frequencies of
IFN-␥, IL-2, and TNF-␣ producing cells that also include cytolytic
and memory functions. As we shall discuss, this is the first description of strong CD4⫹ T cell immunity to a shared nonmutated
self-Ag that is overexpressed in many tumors.

Materials and Methods
Mice
Female BALB/c mice from Taconic Farms were maintained under specific
pathogen-free conditions and used at 7– 8 wk of age under the guidelines
of our Institutional Animal Care and Use Committee.

Reagents
Hamster mAb for CD25 (PC61) was a gift from S. Sakaguchi (Kyoto
University, Kyoto, Japan). We purchased anti-CD16/32, PE-conjugated antiCD8␣ and I-Ad and allophycocyanin-CD11c from BD Biosciences or
eBioscience; goat polyclonal anti-hsurvivin Ab from R&D Systems;
biotin, PE, FITC, PerCP, or allophycocyanin-anti-CD25 (7D4,PC61)
from BD Pharmingen; anti-mouse PE-Foxp3 (FJK-16s) staining kit
from eBioscience; and anti-CD11c microbeads from Miltenyi Biotec.
The other reagents were RPMI 1640 medium and FBS from Life Technologies, CFSE (Molecular Probes), ACK lysing buffer (BioSource),
and 30% BSA solution (Sigma-Aldrich).

Fusion hsurvivin or msurvivin mAbs and other vaccines
The full-length coding region for hsurvivin and msurvivin were amplified
by reverse transcription-PCR of total RNA (1 g) extracted from the U266
and A20 tumor cell lines, respectively. DNA for hsurvivin or msurvivin
was cloned in frame into the C terminus of anti-DEC205 and control mAb
H chains (34). Fusion mAbs were expressed by transient transfection (calcium-phosphate) in 293T cells in serum-free DMEM supplemented with
Nutridoma SP (Roche), purified on protein G-Sepharose (Amersham Pharmacia Biotech), and characterized by SDS-PAGE and Western blotting
(HRP-conjugated sheep anti-mouse IgG (Amersham Biosciences), or HRPconjugated rabbit anti-goat IgG (Southern Biotechnology Associate), as a
secondary to goat anti-hsurvivin (R&D Systems). Unconjugated antiDEC205 mAb expressed by stably transfected Chinese hamster ovary
(CHO) cells was likewise purified. All reagents were verified to be endotoxin free using the Limulus Amebocyte Lysate QCL-1000 from Cambrex.
The MHC-II- restricted immunodominant hsurvivin peptide epitope
(13–27 aa), identified here, was synthesized by the Proteomics Resource
Center of The Rockefeller University. For vaccination, the peptide was
administered s.c. at a concentration of 50 g per mouse with CFA or with
anti-CD40 (25 g) plus poly(I:C) (50 g). Plasmid DNA hsurvivin vaccine
was prepared by cloning the hsurvivin gene into the commercial plasmid
pCMV3-FLAG, using EcoRI and XbaI restriction enzyme sites. Vaccine
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FIGURE 1. Genetic engineering of survivin into the H chain of the antiDEC205 Ab. A, anti-DEC205-hsurvivin, anti-DEC205-msurvivin and their
respective isotype-matched control Abs were analyzed on 4 –15% SDS
PAGE under reducing conditions (m.w. in kDa is indicated). B, Binding
assay to CHO-mDEC205 and control CHO-Neo cells, using graded doses
(0.02–2 g/ml) of anti-DEC205-hsurvivin or anti-DEC205-msurvivin or
the control Ig (clone III/10).

DNA was eluted into saline at 1 g/l; endotoxin in purified DNA was ⬍5
EU/mg. One or two doses of hsurvivin DNA were administered i.m. with
or without electroporation (four pulses of 1-ms duration and field strength
of 200 V cm⫺1). BM-derived DCs (BMDCs) were prepared with GM-CSF
(35). In brief, BM cells were grown in RPMI 1640 medium containing 5%
FCS and the supernatant (3% v/v) from J558L cells transduced with murine
GM-CSF (provided by A. Lanzavecchia, Bellinzona, Switzerland). On day
5, the hsurvivin peptide library, consisting of 36 overlapping 15-mer peptides, was added in some wells at 2 g per ml. Six hours later, LPS (SigmaAldrich) was added at 50 ng/ml for 16 h. On day 6, cells were collected and
washed with PBS. Mice were immunized once s.c and boosted twice at
2-wk intervals, with 3 ⫻ 105 peptide-pulsed or unpulsed BMDCs per
mouse, each time.

Ag targeting and maturation of DCs in vivo
anti-DEC205-hsurvivin or anti-DEC205-msurvivin fusion mAbs were injected i.p., with or without a stimulus for DC maturation, which was 50 g
of poly(I:C) (InvivoGen) and 25 g of 1C10 agonistic anti-CD40 mAb
(36). This combination of stimuli was synergistic in enhancing the primary
survivin-specific T cell response relative to either anti-CD40 mAb or
poly(I:C) alone.

hsurvivin and msurvivin peptides
Overlapping 15-mer peptides, staggered by four amino acids and spanning
the entire sequence of hsurvivin and msurvivin, were synthesized by the
Proteomics Resource Center of The Rockefeller University. The 36-member msurvivin and hsurvivin libraries were divided into four pools of nine
peptides, respectively, for use as a source of Ag in immune assays for
survivin-specific immunity. The respective hsurvivin peptide pools span
from 1 to 45 aa (pool 1), 35 to 88 aa (pool 2), 68 to 108 aa (pool 3), 98 to
142 aa (pool 4) of the hsurvivin protein, and the respective msurvivin pools
span from 1 to 45 aa (pool 1), 35 to 78 aa (pool 2), 68 to 108 aa (pool 3),
98 to 135 aa (pool 4) of the msurvivin protein. Also, two previously identified (37) msurvivin MHC-I-restricted 9-mer peptides (msurvivin (66 –74)
(GWEPDDNPI) and msurvivin (85–93) (AFLTVKKQM) were synthesized.

Flow cytometry for hsurvivin- and msurvivin-responsive T cells
Spleen cells were stimulated with pools of peptides (2 g/ml) or medium
alone in the presence of costimulatory anti-CD28 (2 g/ml; clone 37.51)
for 6 h, adding 10 g/ml brefeldin A (Sigma-Aldrich) for the last 4 h to
accumulate intracellular cytokines. In some experiments, we used previously described MHC-I binding nonamer peptides (above) to look for
CD8⫹ T cell responses. Cells were washed, incubated for 15 min at 4°C
with CD16/32 mAb to block Fc␥R, and stained with FITC- or PEconjugated anti-CD3 (145–2C11) and PerCP-conjugated anti-CD4
(RM4-5) for 20 min at 4°C. The cells were permeabilized (Cytofix/
Cytoperm Plus; BD Biosciences) and stained with allophycocyaninanti-IFN-␥ (XMG 1.2), PE-anti-IL-2 (JESG-5H4), and PE-anti-TNF-␣
(MP6-XT22) mAbs for 15 min at room temperature (BD Pharmingen).
We used a FACSCalibur with data analysis in FlowJo (Tree Star). All
plots were gated on CD3⫹ cells. To assess proliferation of immune T
cells in response to Ag, bulk spleen cells were labeled with CFSE
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In vivo depletion of CD25⫹ T lymphocytes
Three days before vaccination with anti-DEC205-hsurvivin plus anti-CD40
plus poly(I:C), mice were injected with either 100 or 300 g of purified
anti-CD25 IL-2R␣ mAb, a rat IgG1 Ab produced by hybridoma PC61 (38).
The depletion of regulatory T cells was monitored at various time points
following PC61 injection, by staining splenocytes with anti-CD25 (7D4
clone) and anti-Foxp3 Abs, with 300 g being sufficient to deplete most
CD4⫹CD25⫹Foxp3⫹ T cells.

FIGURE 2. DC maturation requirements for primary response to antiDEC205-hsurvivin. A, BALB/c mice were injected i.p. with PBS, 25 g of
1C10 mAb plus 50 g poly(IC), 15 g of anti-DEC205-hsurvivin with
either 25 g of 1C10 mAb or 50 g of poly(I:C), or the combination of
1C10 mAb and poly(I:C). Twenty-one days later, the percentage of IFN-␥⫹
CD4⫹ cells was assessed in CD3⫹ splenic T cells, using hsurvivin and
msurvivin peptide libraries as recall Ag. The averages and SDs for three
similar experiments are shown.

(Molecular Probes) (107 cells per ml, 1 M, 10 min, 37°C) and stimulated with the hsurvivin or msurvivin peptide pools (2 g/ml), medium
alone, or anti-CD3 (0.1 g/ml) and anti-CD28 (2 g/ml; positive control) for 4 days in 1-ml round-bottom tubes. CFSE dilution was assessed
by flow cytometry, often in combination with intracellular cytokine
staining of cells restimulated for the last 6 h of culture.

FIGURE 3. Priming of survivin-specific
CD4⫹ T cells with anti-DEC205-hsurvivin,
but not anti-DEC205-msurvivin, in the presence of anti-CD40 and poly(I:C). A, BALB/c
mice were injected i.p. with PBS, maturation
stimulus alone (25 g of 1C10 mAb and 50
g of poly(I:C)), 15 g of anti-DEC205msurvivin and maturation stimulus, 15 g of
anti-DEC205-hsurvivin and maturation stimulus or the III/10 control Ig-survivin mAbs. 21
days later, the % of IFN-␥⫹ CD4⫹ cells and
IL-2⫹ CD4⫹ cells were assessed in CD3⫹
splenic T cells, using hsurvivin and msurvivin
peptide libraries (survivin mix) as recall Ag.
B, As in A, but the averages and SDs for three
similar experiments with two mice pooled in
each experiment. C, Fifteen micrograms of anti-DEC-hsurvivin Ab in combination with 25
g of anti-CD40 and 50 g of poly(I:C) was
administered i.p. to BALB/c mice. After 21
days, IFN-␥ production was monitored by
ICS, following in vitro restimulation of bulk
splenocytes with single peptides from the reactive hsurvivin and msurvivin peptide pool 1
(2 g/ml). The bold underlined amino acids
differ in hsurvivin and msurvivin.

In vivo cytotoxicity assay
Splenocytes from naive mice were separated and pulsed with hsurvivin or
msurvivin peptide 4 (13–27 aa) (2 mM, 1 h at 37°C, 5% CO2) (39). Peptide-pulsed splenocytes were labeled with a high dose of CFSE (5 M),
while unpulsed splenocytes were labeled with a low dose of CFSE (0.5
M). The CFSEhigh- and CFSElow-labeled populations were then combined
at a 1:1 ratio, and 1.5 ⫻ 107 total cells were injected i.v. into mice. Twelve
hours later, the ratio of CFSElow to CFSEhigh cells was determined in
spleen by flow cytometry. To verify that the targets for killing were
MHC-II positive, we separately analyzed the CFSE-labeled cells according
to labeling with I-Ab-specific mAb (AF6-120.1; BD Pharmingen). The percentage of specific killing was calculated as follows: (1 ⫺ (ratio immune/
ratio naive)) ⫻ 100. Ratio equals the number of events of hsurvivin or
msurvivin peptide-coated targets, divided by the number of events of
reference targets.
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Results
Anti-DEC205 hsurvivin fusion Ab induces a high frequency of
CD4⫹ T cells reactive with both hsurvivin and msurvivin
To assess the capacity of DCs in lymphoid tissues to initiate an
immune response to the self protein, survivin, we prepared fusion
mAbs of anti-DEC205-hsurvivin and anti-DEC205-msurvivin (as
well as control Ig fusion mAbs; Fig. 1) and injected these into
naive BALB/c mice along with anti-CD40 and poly(I:C) to mature
the DCs. The combination of anti-CD40 and poly(I:C) resulted in
a much higher primary immune response than either agent by itself
(Fig. 2). Twenty-one days later, we isolated bulk splenocytes and
restimulated the cells with hsurvivin or msurvivin peptide libraries,
each library consisting of 36 overlapping 15-mer peptides, or
with either of two msurvivin MHC-I-restricted 9-mer peptides
(msurvivin; 66 –74) (GWEPDDNPI) and msurvivin (85–93)
(AFLTVKKQM). Immunity was monitored by intracellular cytokine staining (ICS) for IFN-␥ and IL-2 production, because the
responses were sufficiently large to do so. A primary cytokineproducing immune response was observed for CD4⫹ T cells, but
not CD8⫹ T cells, upon restimulation with the hsurvivin and msurvivin peptide libraries (Fig. 3A), and in BALB/c, but not C57BL/6
mice (data not shown). The use of the previously identified msurvivin, MHC-I-restricted, 9-mer peptides for restimulation did not
induce any detectable immune responses (CD4 or CD8) (data not
shown). Also, we could not elicit IFN-␥ secretion with three different H-2D mouse tumor cells (A20 B cell lymphoma, CT26 colon carcinoma, and methA fibrosarcoma), each of which expressed
survivin mRNA by RT-PCR but low amounts of protein (data not
shown). Only anti-DEC205-hsurvivin and not anti-DEC205-msurvivin, in combination with the DC maturation stimuli, was able to
initiate the production of survivin-specific CD4⫹ T cells, but importantly, both hsurvivin and msurvivin peptide libraries were able
to recall the immune T cells primed with hsurvivin (u). In the first
three experiments of this type, the average frequency of msurvivinreactive IFN-␥ and IL-2-producing cells was 0.36 and 0.45% of
the CD4⫹ T cells in spleen, respectively (Fig. 3B). When we tested
four pools, each comprised of nine overlapping 15-mer peptides,
the major epitope for MHC-II presentation in BALB/c mice was in
pool 1 of both hsurvivin and msurvivin libraries. When we tested
the individual 15-mers in pool 1, the dominant mimetope for in
vivo-processed survivin was between 13 and 27 aa (Fig. 3C). The
sequences of hsurvivin (13–27) (FLKDHRISTFKNWPF) and
msurvivin (13–27) (YLKNYRIATFKNWPF) differ in the NH2terminal amino acids. We conclude that high frequencies of selfreactive CD4⫹ T cells specific for a tumorigenic protein can be
elicited in mice with xenogeneic hsurvivin delivered within
anti-DEC205 mAb.
Comparison of DEC-205 targeting to other methods of survivin
immunization
We compared the response to DC-targeted hsurvivin with other
modes of immunization. When we injected 10 g of the MHC-IIrestricted immunodominant peptide of hsurvivin13–27 with antiCD40 and poly(I:C) maturation, or the combination of hsurvivin13–27 with unconjugated anti-DEC205 mAb, the immune
responses were weak, in contrast with DC-targeted hsurvivin protein with the same maturation stimulus (Fig. 4A). A single dose of
hsurvivin13–27 likewise elicited only weak immunity by the ICS
and ELISPOT assays when we used CFA (Fig. 4A). Immunization
of mice with the MHC-I-restricted peptide epitopes, msurvivin66 –74 or msurvivin85–93, with various different adjuvants
(CFA, poly(I:C), and anti-CD40), did not elicit survivin-specific
CD8⫹ T cell immunity (data not shown). We then tested xenoge-

FIGURE 4. Comparison of DEC205 targeting to other methods of survivin immunization. A, BALB/c mice were injected with either 10 g of
empty anti-DEC205 mAb, 10 g of anti-DEC205-hsurvivin, 10 g of
hsurvivin peptide (13–27 aa) alone or in combination with 10 g of empty
anti-DEC205 mAb, all in the presence of anti-CD40 and poly(I:C).
BALB/c mice were also injected with CFA alone or in combination with
MHC-II-restricted hsurvivin peptide (13–27 aa). Fifteen days later, IFN-␥
production was monitored. Numbers are the percentage of CD4⫹ cells
producing IFN-␥ upon in vitro restimulation with the hsurvivin and msurvivin peptide 4 (13–27 aa). Data represent averages and SD for two similar
experiments. B, BALB/c mice were injected with PBS, anti-DEC205-hsurvivin, or control Ig-hsurvivin (10 g) in the presence of anti-CD40 and
poly(I:C), DNA encoding the hsurvivin gene (30 g) i.m. without or with
electroporation (four pulses of 1-ms duration and field strengths of 200 V
cm⫺1). IFN-␥ production was monitored as in A, but the averages and SD
are for three similar experiments with two mice pooled in each experiment.

neic plasmid DNA vaccination. We performed the DNA immunization experiments with or without electroporation at the time of
injection, because recent evidence suggests that electroporation
improves the effectiveness of DNA vaccination by increasing
DNA uptake and protein expression in various tissues in vivo (40,
41). The immune response (CD4⫹ or CD8⫹) to one or two injections of 30 g of a DNA plasmid encoding the hsurvivin gene was
either weak or undetectable in an IFN-␥ ICS assay, even when
followed by electroporation (four pulses of 1-ms duration and field
strengths of 200 V cm⫺1) (Fig. 4B). Furthermore, the DNA plasmid did not prime CD4⫹ or CD8⫹ T cells for a greater secondary
response or boost with anti-DEC205-hsurvivin in the presence of
anti-CD40 and poly(I:C) (data not shown). We also tested vaccination with BMDCs pulsed with the whole hsurvivin peptide library, consisting of 36 overlapping 15-mer peptides. Three immunizations with unpulsed BMDCs induced a non-Ag-specific CD4⫹
T cell response, and furthermore, the immunizations with BMDCs
pulsed with the hsurvivin peptide library were incapable of generating survivin-specific T cell responses (data not shown). We
conclude that the in vivo targeting of survivin protein to DCs improves CD4⫹ T cell immunization relative to other approaches,
including soluble Ag, DNA, and peptide-pulsed BMDCs.
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FIGURE 5. anti-DEC205-hsurvivin primes
survivin-specific CD4⫹ T cells with good
functional affinity. A, BALB/c mice were
injected with 30, 3, 0.3, and 0.03 g of
either anti-DEC205-hsurvivin or control Ighsurvivin in the presence of anti-CD40 and
poly(I:C). Twenty-one days later, the percentage of IFN-␥⫹CD4⫹ cells and IL2⫹CD4⫹ cells was assessed in CD3⫹splenic T cells, using hsurvivin and
msurvivin peptide libraries (2 M). B, As in
A, but the splenocytes were restimulated in
vitro with different concentrations of hsurvivin and msurvivin peptide libraries ranging from 2 to 0.02 M. One of two similar
experiments.

Responses to anti-DEC205-hsurvivin cross-react efficiently with
msurvivin but not other mouse self-Ags
Central tolerance mechanisms reduce the number of self-reactive
cells, especially those with a higher affinity for Ag recognition (42).
To evaluate the efficiency of anti-DEC205-hsurvivin immunization,
as well as the functional affinity of the immune T cells, we injected
naive BALB/c mice with three different doses (30, 10, and 3 g) of
either anti-DEC205- or control Ig-hsurvivin in the presence of antiCD40 and poly(I:C). Twenty days later, we restimulated in vitro with
different concentrations of hsurvivin or msurvivin peptide libraries
ranging from 2 to 0.02 M. We then measured IFN-␥ and IL-2 secretion by ICS assay (Fig. 5). High frequencies of T cells reactive to
hsurvivin and msurvivin were noted even with an immunizing dose of
3 g of anti-DEC205-hsurvivin, corresponding to ⬃0.3 g of survivin protein. However, more T cells were reactive to hsurvivin vs
msurvivin at all immunizing doses, and the cells recognized the human peptides more efficiently; e.g., at 0.02 M in the immune assay,
the T cells recognized hsurvivin and hardly responded to msurvivin
(Fig. 5B). However, immunization with anti-DEC205-hsurvivin, in
the presence of adjuvants, did not induce serum autoantibodies against
ssDNA, dsDNA, or insulin, as these were not detected by ELISA at
various time points (1, 3, and 6 wk) following immunization (data not
shown). Taken together, these results demonstrate that the response to
anti--DEC-survivin is specific to msurvivin, and as expected for a self

protein, it is lower in frequency and affinity relative to hsurvivin.
Thus, the recognition of msurvivin can be elicited with relatively low
doses of DEC205-targeted Ag and can be recalled with 0.2 M levels
of mimetope peptide.

Long-term memory after primary immunization with
anti-DEC205-hsurvivin
To begin to assess the generation of memory, we tested whether
immunized mice would develop secondary responses of a greater
magnitude than the primary response. We immunized naive
BALB/c mice with either PBS or anti-DEC205-hsurvivin (5 g)
with anti-CD40 and poly(I:C). Sixty days later, each group of mice
was boosted with PBS, anti-DEC205-hsurvivin (10 g) alone, or
anti-DEC205-hsurvivin (10 g) with either anti-CD40 or poly(I:C)
or the combination of anti-CD40 and poly(I:C), as maturation
stimuli. Seven days later, we isolated bulk splenocytes and performed both ICS for IFN-␥ production, in a rapid restimulation
assay for effector memory cells (Fig. 6A) and proliferation by
CFSE dilution as well as CD62L expression, during 4 days of
response to Ag in culture (Fig. 6B). As shown in Fig. 6A, persisting
effector cells were no longer detected in the nonboosted groups
(see PBS column), but a higher percentage of survivin-specific T
cells, relative to the primary response, was noted in the boosted
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FIGURE 6. Long-term memory after primary immunization with anti-DEC205-hsurvivin in the presence of adjuvant. BALB/c mice were immunized with
either PBS or anti-DEC205-hsurvivin with anti-CD40 (25 g) and poly(I:C). Sixty days later, each group of mice was boosted with PBS, anti-DEC205-hsurvivin
(5 g) alone, or anti-DEC205-hsurvivin (5 g) with either anti-CD40 (25 g) or poly(I:C) (50 g) or the combination of anti-CD40 and poly(I:C), as maturation
stimuli. A, Seven days after boosting, ICS for IFN-␥ was performed using 6-h restimulation with hsurvivin and msurvivin peptide mixtures (2 M). Arrowheads
indicate the secondary responses to anti-DEC205-survivin without adjuvant, while arrows indicate the responses with adjuvant. B, Seven days after boosting, bulk
splenocytes were also CFSE labeled and cultured for 4 days with the hsurvivin and msurvivin peptide mixtures (2 M). On the fourth day of culture, proliferation
was assayed by CFSE dilution in a FACS assay, as shown for msurvivin (slanted arrows). Numbers are the percentage of CD62LlowCD4⫹ proliferating T cells.
One of two similar experiments.

mice (see arrows). When we assessed memory with a CFSE dilution assay, we again found that boosting with anti-DEC205-hsurvivin, even without full DC maturation, expanded the frequency of
proliferating cells, which were both CD62Llow (Fig. 6B; see first
arrow from left) and capable of producing IFN-␥ (data not shown).
Although DC maturation stimuli were necessary during the primary immunization, some degree of boosting was evident in the
absence of these maturation stimuli (Fig. 6; e.g., black arrowheads
in A). These data indicate that DC-based immunization with antiDEC205-hsurvivin induces memory cells that have reactivity to
msurvivin.
CD25⫹ T cell depletion amplifies the CD4⫹ T cell response to
anti-DEC205-hsurvivin
Because immune responses to self and foreign Ags can be negatively regulated by CD25⫹ suppressor T cells (43, 44), we examined whether depletion with an anti-CD25 mAb (clone PC61) can
increase effector CD4⫹ T cell responses. We injected naive
BALB/c mice with either PBS or 300 g of PC61, and 3 days later,
we immunized each group with PBS, anti-CD40 and poly(I:C),
anti-DEC205-hsurvivin (15 g per mouse) in the presence of antiCD40 and poly(I:C), or control III/10-hsurvivin in the presence of
anti-CD40 and poly(I:C). We verified at the time of immunization
and 21 days later that CD4⫹CD25⫹Foxp3⫹ T cells were depleted
by PC61 (data not shown). We found that the depletion of
CD4⫹CD25⫹ regulatory T cells with 300 g of PC61 amplified
the survivin-specific CD4⫹ T cell response, induced by immunization with anti-DEC205-hsurvivin in the presence of anti-CD40
and poly(I:C) (Fig. 7). A dose of 100 g of PC61 did not amplify
immunity but also only reduced the number CD4⫹CD25⫹ T cells
by ⬃50% (data not shown). We also observed sizable increases in

immunity to both hsurvivin and msurvivin when we measured T
cell proliferation in a CFSE dilution assay (see arrows in Fig. 7C)
and increased IFN-␥ and IL-2 production in an ICS assay (Fig. 7,
A and B). However, the enhanced survivin-specific CD4⫹ T cell
response was only seen upon immunization with anti-DEC205hsurvivin and not anti-DEC205-msurvivin (data not shown), and
PC61 treatment was not capable of allowing for the development
of a CD8⫹ T cell response following immunization with antiDEC205-hsurvivin. These data indicate that CD4⫹ T cell immune
responses to a self tumor Ag can be enhanced by treatment of mice
with PC61 mAb at a dose sufficient to deplete CD4⫹CD25⫹
Foxp3⫹ suppressor T cells for prolonged periods.
Immunization with anti-DEC205-hsurvivin induces cytolytic
CD4⫹ T cells
To determine whether the immunization protocol in Fig. 7 could
expand cells with in vivo cytolytic function, we immunized control
mice or mice depleted of regulatory T cells with PC61 with antiDEC205-hsurvivin and anti-CD40 and poly(I:C), or with control
Ig-hsurvivin. Thirty-five days postimmunization, we injected the
mice with 15 ⫻ 106 BALB/c spleen cells of two types: one pulsed
with peptide 4 from the hsurvivin or msurvivin peptide pool 1 and
labeled with CFSEhigh (5 M) and the other unpulsed but
CFSElow-labeled (concentration of 0.5 M). Effective and specific
CTLs were observed in the lymph nodes (data not shown) and
spleens of mice immunized with anti-DEC205-hsurvivin in the
presence of anti-CD40 and poly(I:C), with greater responses upon
depletion of CD4⫹CD25⫹ regulatory T cells (see arrows in Fig. 8,
A, top row, and C, left). After 12 h in vivo, ⬃50% of the CFSEhighlabeled, MHC-IIhigh donor cells pulsed with hsurvivin peptide
were lost, compared with the reference CFSElow labeled, unpulsed
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FIGURE 7. Depletion of CD4⫹
CD25⫹ regulatory T cells amplifies
survivin-specific CD4⫹ T cell responses to anti-DEC205-hsurvivin
plus anti-CD40/poly(I:C). BALB/c
mice were injected i.v. with either
PBS or 300 g of PC61, the latter to
deplete the subset of CD4⫹CD25⫹
Foxp3⫹ T cells. Three days later,
each group was immunized with
PBS, anti-CD40 (25 g) and poly(I:C)
(50 g), anti-DEC205-hsurvivin, or
control III/10 Ig-hsurvivin (15 g per
mouse) in the presence of anti-CD40
and polyIC. A and B, Twenty-one days
later, the percentages of IFN-␥⫹CD4⫹
cells and IL-2⫹CD4⫹ cells were assessed in gated CD3⫹-splenic T cells
using hsurvivin and msurvivin peptide
libraries. C, Bulk splenocytes were also
CFSE labeled and cultured with the
hsurvivin and msurvivin peptide mixtures. Proliferation was evaluated by
CFSE dilution at 4 days. Numbers are
the percentage CD62LlowCD4⫹ proliferating T cells. D, As in A, but the averages and SD of the percentage of
IFN-␥⫹CD4⫹ T cells, as shown for
three similar experiments with two
mice pooled in each.

donor population, in the immunized mice depleted of CD4⫹
CD25⫹ regulatory T cells. The percentage loss of CFSEhigh-labeled, MHC-IIhigh donor cells pulsed with hsurvivin peptide was
reduced to 38% in immunized mice not depleted of CD4⫹CD25⫹
regulatory T cells, (see arrows in Fig. 8, A, second row, and C,
left). CFSEhigh-labeled, MHC-IIhigh donor cells pulsed with msurvivin peptide showed a smaller ⬃20% level of killing (see arrows
in Fig. 8, B and C, left). To establish the importance of MHC-II
presentation, we verified that peptide-pulsed MHC-IIlow donor
cells in the same recipient mouse were not eliminated (right half of
Fig. 8). Therefore, the CD4⫹ T cells that are actively immunized
to msurvivin are capable of some cytolytic activity.

for CD4-directed killing in vivo, following immunization with antiDEC205-hsurvivin, in the presence of anti-CD40 and poly(I:C), after
depletion of CD4⫹CD25⫹ regulatory T cells (using PC61), we evaluated production of FasL, perforin, and TNF-␣ by hsurvivin and
msurvivin peptide-responsive IFN-␥ producers in an ICS assay. Neither FasL nor perforin could be detected (data not shown). However,
the ICS data show that CD4⫹ T cells, from mice immunized with
anti-DEC205-hsurvivin with anti-CD40 and poly(I:C), following depletion of CD4⫹CD25⫹ regulatory T cells, produce TNF-␣, in
response to in vitro stimulation of hsurvivin and msurvivin peptide
libraries (Fig. 9).

Immunity to anti-DEC205-hsurvivin includes a high frequency of
TNF-␣-producing CD4⫹ T cells

Discussion

Several effector mechanisms have been demonstrated in the lysis of
target cells in vitro by CD4⫹ T cells, including TNF-␣ (45), Fasligand (FasL) (46), and perforin (47). To implicate a mechanism

Mutated self-Ags that are associated with tumor development can
serve as rejection Ags in mice (45, 48, 49). These mutant self-Ags can
contribute to tumorigenesis, but different mutations are typically

Classes of tumor Ags
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FIGURE 8. Immunization with anti-DEC205hsurvivin and adjuvants induces long-lived, survivinspecific, MHC-II-restricted killing. BALB/c mice
were injected i.v. with either PBS or 300 g of
PC61. Three days later, each group was immunized
with PBS, anti-CD40 (25 g) and poly (I:C) (50
g), anti-DEC205-hsurvivin, or control III/10 Ighsurvivin (15 g per mouse) in the presence of antiCD40 and poly(I:C). Thirty-five days later, the immunized mice were injected i.v. with 7 ⫻ 106 each
of syngeneic splenocytes pulsed with hsurvivin (A)
or msurvivin (B) peptide 4 (CFSEhigh) and unpulsed
(CFSElow), to detect active killer cells in the lymph
nodes and spleen (see arrows). Histograms are gated
on MHC-IIhigh cells (top and bottom left panels), or
MHC-IIlow cells (top and bottom right panels). C,
Averages and SD for two experiments for percentage lysis of hsurvivin or msurvivin peptide-pulsed
targets as in A and B, for MHC-IIhigh cells (left) and
MHC-IIlow cells (right).

found in different examples of a particular type of tumor (50). In
contrast, many of the alterations that are shared among tumors and are
likely to drive different components of carcinogenesis represent normal, nonmutated self-Ags (51–55). Immune responses to these nonmutated self-Ags in tumors are typically weak, primarily due to central and peripheral mechanisms for self tolerance. Nonetheless, the
thymus allows for the formation of low-affinity T cells specific to
self-Ags (56, 57). The purpose of this paper was to use as Ag a
nonmutated self protein important in tumorigenesis (in our case, sur-

vivin) and identify mechanisms required to elicit strong immunity,
particularly a CD4⫹ helper T cell response. By strong, we mean T cell
responses that are 0.1–1.0% of total CD4⫹ T cells, involve the expression of IFN-␥, IL-2, and TNF-␣, and are associated with T cell
memory, including proliferation.
A new strategy for enhancing CD4⫹ T cell immunity to tumors
Cancer immunology and immunotherapy has focused on CD8⫹
CTL, due to their ability to recognize and lyse MHC-I⫹ tumor

FIGURE 9. Survivin-specific CD4⫹ T
cells produce TNF-␣. BALB/c mice were injected i.v. with 300 g of PC61. Three days
later, each group was immunized with PBS,
anti-CD40 and poly(I:C), anti-DEC205hsurvivin, or control III/10-Ig hsurvivin (15
g per mouse) in the presence of anti-CD40
and poly(I:C). Twenty-one days later, the
percentages of TNF-␣-⫹CD4⫹ cells relative
to isotype control Ab were assessed in gated
CD3⫹-splenic T cells using hsurvivin and
msurvivin peptide libraries.
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cells (4, 58). Various strategies have been developed to induce
CD8⫹ T cell responses to tumor Ags, including adoptive transfer
of tumor Ag-specific CD8⫹ T cells (5), engineering of MHC-I
binding tumor peptides into viral (59) or bacterial (60) expression
vectors, transfection of DCs with defined RNA for tumor Ags or
bulk RNA from tumors (61, 62), and loading of DCs with MHC-I
binding tumor peptides or tumor cell lysates (63, 64) and naked
plasmid DNA (65, 66). To date, trials in cancer patients have demonstrated that these approaches are able to induce some Ag-specific CD8⫹ T cell responses, including IFN-␥ production (63, 67).
However, the CD8⫹ T cell responses have typically been short
lived (68), small in magnitude relative to antiviral responses, and
typically not associated with objective tumor regression in the patients with advanced cancer that have been tested (69 –71).
To improve on the induction of tumor immunity to tumors, one
possibility is to consider a need for CD4⫹ T cell help to sustain
memory CD8⫹ T cells. “Helped” CD8⫹ T cells are able, upon
encounter with their cognate tumor Ag, to proliferate and acquire
cytolytic capabilities (72). Thus, the induction and efficacy of a
vaccine-induced antitumor response, even when aimed at solid tumors that themselves lack MHC-II (6), in many cases requires the
cooperation of CD4⫹ Th cells (73).
In this study, we evaluated the hypothesis that the direct targeting of a xenogeneic form of a self-Ag, survivin, to maturing DCs
in lymphoid tissues via the DEC205 receptor might be able to
overcome barriers to eliciting immunity to conserved self proteins
important in tumorigenesis. Previously, it was shown that xenogeneic forms of an Ag were better able to induce CD8⫹ T cell
responses to the corresponding self protein (65). To target hsurvivin to mouse DCs in situ, we used a strategy developed previously with foreign model (31, 34) and microbial (32, 33) Ags. In
this approach, antigenic peptides or proteins were engineered as
fusion proteins in the H chain of anti-DEC205/CD205 mAbs. Abbased targeting then enhanced Ag presentation in vivo to CD4⫹
and CD8⫹ T cells at least 100-fold relative to nontargeted Ag. We
found that DC targeting with anti-DEC205-hsurvivin fusion mAb
could overcome tolerance to this overexpressed self/tumor Ag and
induce survivin-specific CD4⫹ T cell immunity of improved quantity and quality relative to prior reports with other shared, nonmutated tumor Ag vaccines.
The basis for the improved immunity via anti-DEC205 targeting
relative to other standard approaches could be severalfold: 1) Ab
targeting ensures that large numbers of DCs systemically are presenting Ag (31), whereas other approaches typically load small
numbers of DCs in draining lymph nodes; 2) there is evidence that
DEC205 is a specialized endocytic receptor, able to recycle
through MHC-II⫹ compartments and markedly enhance presentation on MHC-II (74); and 3) DEC205 is expressed on a subset of
DCs that may be more effective in inducing Th1 T cell immunity
(75). Resolution of these possibilities might benefit from targeting
approaches that examine other DC subsets and other receptors on
the DEC205⫹ DC subset.
Evidence for improved CD4⫹ T cell immunity to survivin
following targeted delivery to maturing DCs in vivo
We obtained several lines of evidence for improved CD4⫹ T cell
immunity to survivin following targeted delivery to maturing DCs
in vivo. First, the CD4⫹ T cell response to survivin was sizable
relative to prior studies on this limb of cell-mediated immunity.
Following a single immunization of naive BALB/c mice with antiDEC205-hsurvivin, but not anti-DEC205-msurvivin, in the presence of anti-CD40 and poly(I:C) as DC maturation stimuli, 0.36 ⫾
0.05% of the CD4⫹ T cells made IFN-␥ and 0.45 ⫾ 0.05% made
IL-2 in response to msurvivin, while the response to hsurvivin was
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2- to 3-fold greater. Only 3–10 g of the anti-DEC205-hsurvivin
(which corresponded to 0.3–1.0 g of hsurvivin protein) could
generate these responses. With an IFN-␥ ELISPOT assay, the
same immunization induced ⬃300 spots per 3 ⫻ 105 CD4⫹ T cells
upon in vitro hsurvivin peptide restimulation vs 10 spots per 3 ⫻
105 CD4⫹ T cells in the absence of in vitro peptide restimulation
(data not shown).
Although we were unable to induce survivin-specific, CD4⫹ T
cells by injecting DCs loaded with survivin peptide, others have
succeeded in inducing some IFN-␥ producing cells by an
ELISPOT assay, following multiple doses of DCs pulsed with a
melanoma peptide in humans with cancer (76). Soares et al. (53)
also immunized mice with three injections of human MUC-1
peptide-pulsed DCs at 3-wk intervals. The CD4⫹ MUC-1 T cell
response was ⬃160 ELISPOTs in immune lymph nodes with a
background of 120 spots. A current limitation to the use of ex
vivo-derived DCs as adjuvants is that only a few percent of the
injected cells arrive in the lymph nodes, whereas DEC-targeting
loads large numbers of DCs that express DEC and systemically
(31).
Other groups have used MHC-II-restricted peptide epitopes of
self/tumor Ags (e.g., hTERT, wild-type p53, carcinoembryonic Ag
(CEA)) in their soluble form. In these studies, immunization required high doses of Ag and two or three injections to overcome
tolerance and induce a CD4⫹ T cell response (45, 77). For example, HLA-DR4-transgenic mice had to be immunized twice with
100 g per injection of an MHC-II-restricted peptide from human
telomerase reverse transcriptase (hTERT), emulsified in CFA, to
detect hTERT-specific CD4⫹ T cell responses (77). After two immunizations, the hTERT-specific CD4⫹ T cell responses were 140
spots per 106 bulk splenocytes upon in vitro hTERT peptide restimulation in an IFN-␥ ELISPOT assay vs 10 spots per 106 bulk
splenocytes in the absence of in vitro peptide restimulation. Similarly, high doses (50 g per mouse) of wild-type and mutant
mouse p53 peptides in CFA were necessary for the induction of
p53-specific CD4⫹ T cell responses in naive mice (45).
A second consequence of DEC205 targeting was that the immune T cells had a relatively good functional affinity. We have
used mimetope peptides derived from an overlapping library of
15-mers spanning the full length of hsurvivin or msurvivin rather
than naturally processed peptides, but even so, relatively low doses
of the mimetope peptides (0.02 g/ml for the human peptide and
0.2 g/ml for the mouse peptide) were required to activate the
population of primed T cells in the immune assays. Previous studies have used 10- to 500-fold higher peptide concentrations for in
vitro restimulation of bulk splenocytes (54, 55, 77). For example,
to elicit the CD4⫹ T cells primed in vivo with hTERT peptide
emulsified in CFA (in HLA-DR4-transgenic mice), bulk splenocytes were restimulated in vitro with 20 g/ml hTERT peptide
(77). Similarly, to elicit T cells primed and boosted in vivo with
recombinant vaccinia-CEA, the CD3⫹ T cells were restimulated in
vitro with 50 g/ml human CEA (54, 55).
A third consequence, which has not been reported with other
strategies to immunize helper T cells, was that the CD4⫹ T cell
response was long lasting, and upon boosting, effector memory
was noted. The use of a maturation stimulus during the primary
immunization was necessary to induce long-term effector memory
CD4⫹ T cells (CD62Llow) that could be boosted with antiDEC205-hsurvivin. However, memory T cells with a central memory phenotype (CD44highCD62Lhigh) were not detected. A similar
result was reported recently by Benigni et al. (78). They found that
injection of LACK-expressing tumor cells into 16.2␤ mice (LACK
is a protein Ag from Leishmania major and 16.2 mice express a
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TCR Tg ␤-chain derived from a LACK-specific hybridoma) induces the generation of CD4 effector T cells (CD62Llow and capable of IFN-␥ production) in tumor-draining lymph nodes (78).
The authors also report that LACK-specific CD4⫹ T cells of a
central memory phenotype (IL-2⫹, CD44highCD62Lhigh) could be
found within the peripheral lymphoid tissues of mice, only if
LACK-expressing tumors (the only cell type in the mouse expressing the Ag) were surgically resected. This result is in accordance
with infectious disease models, which have shown that complete
Ag clearance favors the development and survival of central T cell
memory (79, 80). The absence of central memory CD4⫹ T cells in
our system may thus be explained by the fact that survivin is a
normal self-Ag and is thus able to stimulate the memory cells
induced by DEC205 targeting. Alternatively, DEC205 targeting
may induce predominantly effector-type memory cells.
Fourth, we noted that the CD4⫹ T cell-dependent immune response could be further amplified if CD4⫹CD25⫹ regulatory T
cells were first depleted with PC61 anti-CD25 mAb before immunization. Sakaguchi and coworkers (38) have emphasized the amplifying effect of CD25 depletion in most experimental mouse tumors. Furthermore, Schreiber et al. (81) have reported a selective
accumulation of CD4⫹CD25⫹ T cells inside tumors, especially at
late stages of tumor progression, while depletion of these T cells
during the effector phase successfully enhanced antitumor immunity. Previous studies demonstrating enhanced immunity following depletion of CD4⫹CD25⫹ regulatory T cells with PC61 mAb
have used either viral tumor Ags or MHC-I-restricted tumor/selfAgs (82– 84). Casares et al. (82) studied an MHC-II-restricted
epitope derived from the sequence of murine leukemia virus gp70
envelope protein, which is a tumor rejection Ag expressed by
CT26 but not an authentic self-Ag. Jones and Gallimore (83) demonstrated that treatment of mice with anti-CD25 mAb facilitated
long-term CD4⫹ T cell-mediated tumor immunity, as indicated by
the fact that these cells were able to reject B16F10 tumor cells
when injected into B6.RAG2⫺/⫺ mice in the absence of CD8⫹ T
cells. When specific melanocyte differentiation Ags were tested, all
the mice that had rejected melanoma ⬃8 mo previously and that
exhibited signs of depigmentation were also protected against infection with recombinant vaccinia vector-expressing tyrosinase,
but not Trp2, gp100, MART-1, or Trp1 (83). Other studies have
concentrated on demonstrating enhanced CD8⫹ T cell responses,
upon depletion of CD4⫹CD25⫹ regulatory T cells, to MHC-Irestricted tumor/self-Ags, such as gp100 (84), Trp2 (85), and Her2/
Neu (86) in various tumor models. Our findings represent the first
time that depletion of regulatory T cells has been shown to
augment CD4⫹ T cell reactivity to a shared nonmutated
tumor/self-Ag.
Fifth, we were also able to elicit survivin-specific, cytolytic
CD4⫹ T cells. The survivin-dependent CTLs acted on MHC-IIhigh
targets in vivo, and we were able to identify high frequencies of
TNF-␣-producing CD4⫹ T cells as well. Several effector mechanisms have been demonstrated for the lysis of target cells in vitro
by CD4⫹ T cells, including TNF-␣ (87), FasL (46), and perforin
(47). Neither FasL nor perforin could be detected on our survivinresponsive T cells (data not shown). Therefore TNF-␣ is a possible
mediator of the lysis we observed.
Inability to observe CD8⫹ T cell responses to survivin following
DEC-205 targeting
Despite the capacity of anti-DEC205-targeting to induce survivinspecific, CD4⫹ T cell immunity, we were unable to detect CD8⫹
T cell immunity even when we used previously described MHC-I
binding survivin peptides for BALB/c mice (37). Previous studies
have used survivin as a potential cancer vaccination target and
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have shown the induction of survivin-specific CD8⫹ T cell responses, leading to protection from a survivin-expressing tumor
challenge. For example, vaccination of BALB/c mice with 5 ⫻ 105
DCs transfected with murine survivin-RNA (three s.c. injections)
leads to long-term resistance to challenge by A20 lymphoma (88).
Two MHC-I-restricted peptide epitopes derived from the murine
survivin protein were identified, and BALB/c mice treated with
syngeneic DCs pulsed with the two survivin epitopes were able to
reject an otherwise lethal tumor inoculation of the A20 B cell
lymphoma (37). In addition, a DNA vaccine encoding murine survivin and the secretory chemokine CCL21, orally delivered by
doubly attenuated Salmonella typhimurium (dam⫺ and AroA⫺) to
secondary lymphoid organs, elicited marked activation of DCs and
an effective CD8⫹T cell immune response. This resulted in eradication or suppression of pulmonary metastases of non-small cell
lung carcinoma in both prophylactic and therapeutic settings in
C57BL/6J mice (89).
In contrast, we have been unable to induce a CD8⫹ T cell response to these previously defined survivin peptides by immunizing with peptides in CFA (both 15-mer peptide mixtures or two
nonomeric MHC-I binding peptides), or peptides pulsed onto DCs,
or plasmid DNA encoding survivin under the control of a CMV
promoter, or DCs loaded with dying A20 lymphoma cells. We
think that two factors may have limited the induction of CD8⫹ T
cell immunity. The repertoire for this self protein may be too small
to allow for the detection of immunity with only one or two immunizations. Secondly, in the case of the anti-DEC205 targeting
strategy, the current mAb may be suboptimal for eliciting CD8⫹ T
cells, although clearly some CD8⫹ T cell immunity is observed
with anti-DEC targeting of foreign proteins like OVA, HIV gag,
and malaria circumsporozoite protein (31–33).

Inability to observe protection against A20 lymphoma growth
following DEC-205 targeting
We also were unable to document protection of immunized mice to
an in vivo tumor challenge by A20 lymphoma cells expressing
msurvivin mRNA (data not shown). This result is in contrast to our
earlier data with anti-DEC205-OVA conjugates, which when administered in conjunction with anti-CD40, proved to be a superior
means to protect mice against an OVA-expressing tumor challenge
(31). One possible explanation for this discrepancy is that survivin
is a self-Ag that has presumably induced some tolerance at thymic
and/or peripheral levels, in contrast to the foreign Ag, OVA. Furthermore, the MHC-I-restricted peptide epitope of the OVA protein (SIINFEKL) may be easier to process or following processing,
it binds more stably to the MHC-I molecule, leading to enhanced
CD8⫹ T cell activation, compared with candidate CD8⫹ epitopes
in the survivin protein. We also note that expression of msurvivin
in mouse tumor cell lines like A20 lymphoma is quite low, using
immunoblotting or FACS with goat anti-survivin polyclonal Ab
(data not shown). This may have reduced the chance for recognition by T cells immunized by anti-DEC-survivin Abs. We are currently testing other immunization strategies to determine whether
CD8⫹ T cell responses to survivin can be induced in the BALB/c
mice used in our experiments.
In summary, targeting via the DEC205 receptor on maturing
DCs within lymphoid tissues allows CD4⫹ T cell immunity to be
generated to a shared nonmutated self-Ag that is overexpressed in
human cancers (19 –21). Therefore, the CD4⫹ helper T cell repertoire need not be blind to hyperexpressed self-Ags that drive the
pathogenesis of cancer.
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